Nasonex (Mometasone Furoate)

Mometasone furoate is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors in nasal tissues. This binding alters gene transcription, suppresses inflammatory cytokines, and reduces the activity of immune cells, leading to decreased inflammation of the nasal mucosa.

The dose of Nasonex is determined by a qualified prescriber based on the patient’s age, condition and response to therapy. Typical regimens involve one or two sprays per nostril once daily, but exact instructions should be obtained from the prescribing healthcare professional.

The safety of Nasonex in pregnancy and lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before starting treatment.

To order Nasonex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasonex (mometasone furoate) and other nasal corticosteroids such as fluticasone or budesonide share a similar anti‑inflammatory mechanism. Mometasone is often noted for its high receptor affinity, which may allow effective symptom control at low daily doses, but clinical choice depends on individual response, tolerability and prescriber preference.

Nasonex should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the spray after the indicated expiration date.

Nasonex is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press down on the pump while breathing in gently through the nose. The process is repeated for the other nostril if prescribed.

Serious risks, though uncommon, include nasal septal perforation, severe or persistent nosebleeds, adrenal suppression with prolonged high‑dose use, opportunistic fungal infections of the nasal passages, and severe allergic reactions such as anaphylaxis. Patients should seek medical attention if any of these occur.

Nasonex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients who have active untreated infections of the nasal passages or recent nasal surgery unless directed by a physician.